Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Andrew_Robbins
|
| gptkbp:clinicalTrialPhase |
conducts clinical trials for rare cancers and mast cell diseases
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
targeted therapies for rare diseases
|
| gptkbp:focusesOn |
precision therapies for genetically defined diseases
|
| gptkbp:formerName |
gptkb:Unum_Therapeutics
|
| gptkbp:foundedYear |
2014
|
| gptkbp:headquartersLocation |
gptkb:Waltham,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cogent Biosciences
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:bezuclastinib
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:COGT
|
| gptkbp:website |
https://www.cogentbio.com/
|
| gptkbp:bfsParent |
gptkb:Unum_Therapeutics
|
| gptkbp:bfsLayer |
7
|